SpinChip

About SpinChip

SpinChip Diagnostics AS, a Norwegian medical technology firm established in 2011, is focused on the in vitro diagnostics (IVD) market. The company is developing a point-of-care (POC) platform designed to deliver laboratory-quality results from a single drop of blood within minutes. This platform centers around a disposable, single-use cartridge and a compact analyzer instrument, aiming to decentralize diagnostic testing from central laboratories to locations like doctors' offices, clinics, and hospital emergency rooms.

The core of SpinChip's technology lies in its proprietary microfluidic platform, which integrates advanced fluid dynamics and nanocoatings to handle blood samples. The process involves placing a small blood sample into the cartridge, which is then inserted into the analyzer. Inside the cartridge, plasma is separated from whole blood, and the sample is moved into a reaction chamber where it mixes with dried reagents specific to the test being performed. This entire analysis is automated within the instrument, which manages the fluidics and reads the results, providing a quantitative answer quickly.

The company's initial focus is on cardiac diagnostics, particularly developing a high-sensitivity cardiac troponin I (hs-cTnI) test. This test is critical for the rapid diagnosis of heart attacks (acute myocardial infarction) in emergency settings, where speed and accuracy are paramount. The business model appears to be based on the sale of the analyzer instruments and the recurring revenue from the single-use, test-specific cartridges. By offering a broad menu of tests on a single platform, SpinChip aims to provide a cost-effective and efficient solution for healthcare providers, reducing the need for multiple different POC devices.

SpinChip Diagnostics was founded by a team of entrepreneurs, including Stig Morten Borch, Øystein Fiskaa, and Mathias Uhlen, leveraging their collective experience in medical technology and diagnostics. The development is a collaborative effort involving several partners, including the University of Oslo and Oslo University Hospital, which provides a strong clinical and research foundation for the technology. The company has secured significant funding through various investment rounds to advance its technology from the research and development phase toward regulatory approval and commercial launch.